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Abstract
Multiple sclerosis (MS) is a debilitating, chronic demyelinating disease of the central nervous system affecting over 2 million
people worldwide. The TAM family of receptor tyrosine kinases (TYRO3, AXL and MERTK) have been implicated as important
players during demyelination in both animal models of MS and in the human disease. We therefore conducted an
association study to identify single nucleotide polymorphisms (SNPs) within genes encoding the TAM receptors and their
ligands associated with MS. Analysis of genotype data from a genome-wide association study which consisted of 1618 MS
cases and 3413 healthy controls conducted by the Australia and New Zealand Multiple Sclerosis Genetics Consortium
(ANZgene) revealed several SNPs within the MERTK gene (Chromosome 2q14.1, Accession Number NG_011607.1) that
showed suggestive association with MS. We therefore interrogated 28 SNPs in MERTK in an independent replication cohort
of 1140 MS cases and 1140 healthy controls. We found 12 SNPs that replicated, with 7 SNPs showing p-values of less than
10
25 when the discovery and replication cohorts were combined. All 12 replicated SNPs were in strong linkage
disequilibrium with each other. In combination, these data suggest the MERTK gene is a novel risk gene for MS
susceptibility.
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Introduction
Multiple sclerosis (MS) is a chronic demyelinating and
inflammatory disease of the central nervous system (CNS),
affecting mainly individuals of European ancestry [1]. The disease
is characterised by CNS demyelination, loss of oligodendrocytes,
inflammation, as well as neurodegeneration. Susceptibility to MS
is thought to involve a complex interplay of genetic and
environmental factors, with the HLA-DRB1*1501-DQBI*602
(HLA-DR15) haplotype in the major histocompatibility complex
(MHC) being the predominant genetic risk factor [2,3]. Other
genetic associations have been observed and replicated in IL7R
[2], IL2RA [2], CLEC16A [4,5], CD226 [5], CD6 [6], IRF8 [6],
TNFRSF1A [6], STAT3 [7], KIF21B [8], TMEM39A [8] and TYK2
[9].
The TAM receptors (TYRO3, AXL and MERTK) comprise a
family of structurally related receptor tyrosine kinases that have
two identified ligands: GAS6 and protein S [10,11,12]. TAM
receptor signaling has been implicated in several biological
processes, including cell survival and proliferation [13,14,15,16],
immune regulation [17,18,19] and phagocytosis of apoptotic cells
[19,20,21]. As these are all key processes involved in demyelin-
ation, several recent studies have examined the role of these
receptors in animal models of MS, as well as in the human disease.
Previous work in our laboratory examined the course of
cuprizone-induced demyelination in mice lacking the TAM
receptor ligand GAS6. Cuprizone is a neurotoxin that when
incorporated into the feed of mice, induces specific and focal T
cell-independent demyelination within the CNS, particularly in
the corpus callosum [22,23,24]. Following 3 weeks of cuprizone-
challenge we observed greater demyelination, which corresponded
with increased oligodendrocyte loss and microglial activation in
the absence of GAS6 compared with wild-type mice [25]. In a
separate study, AXL receptor knockout mice displayed an overall
reduction in myelination following 6 weeks of cuprizone-challenge,
as well as a delay in microglial activation and the clearance of
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between the phenotypes of the ligand and single receptor knockout
mice during cuprizone-challenge highlights the complexity of
TAM receptor signaling, but more importantly, these studies
clearly show that loss of TAM receptor signaling is accompanied
by increased demyelination in the cuprizone model.
The studies by Binder et al. [25] and Hoehn et al. [26] have
focused on experimental animals, but a recent study has
implicated the TAM receptors as important players in human
MS as well. In a study of human MS lesions, levels of soluble forms
of the TAM receptors, which can act as decoy receptors for the
membrane-bound receptors, were compared in chronic silent MS
lesions, chronic active MS lesions and healthy controls. It was
found that levels of soluble AXL were higher in chronic silent
lesions, while levels of soluble MERTK were higher in chronic
active lesions compared with controls [27]. These elevated levels of
soluble AXL and MERTK also correlated with low levels of GAS6
within the lesions [27], suggesting that loss of TAM receptor
signaling may prolong MS lesion activity. Taken together, these
studies implicate TAM receptor signaling as playing a key role in
several processes affecting the outcome of demyelination in both
animal models as well as human MS.
Given the aforementioned results, we hypothesized that polymor-
phismsin the TAM receptor or ligand genes would be associated with
MS and thus also be involved in the aetiology of the disease. In a
recent genome-wide association study (GWAS) conducted by the
Australian and New Zealand Multiple Sclerosis Genetics Consortium
(ANZgene) [28], several single nucleotide polymorphisms (SNPs)
within the MERTK gene (Chromosome 2q14.1, Accession Number
NG_011607.1) showed suggestive association with susceptibility to
MS,whileSNPs withintheTYRO3,AXL,GAS6 and PROS1 genes did
not show any suggestive associations. We therefore conducted a
replication study with a candidate gene approach to validate this
finding by genotyping 28 common SNPs within MERTK in an
independent cohort of 1140 MS cases and 1140 healthy controls. In
this study, we identify 12 replicated SNPs that are significantly
associated with MS susceptibility, suggesting the MERTK gene as a
novel risk gene involved in MS susceptibility.
Methods
Study subjects
The Melbourne Health Human Research Ethics Committee
and the Australian Bone Marrow Donor Registry Ethics
Committee granted approval for this research. Written consent
was given by the subjects for their information to be stored in the
study database and used for research.
Genotype data from a GWAS conducted by the ANZgene
Consortium [28] was used as a discovery dataset to search the five
TAM receptor and ligand genes for SNPs that showed suggestive
association with MS susceptibility. Following quality control as
outlined in the ANZgene GWAS [28], this dataset consisted of
1618 MS cases of European ancestry from Australia and New
Zealand, and 3413 healthy controls of European ancestry from
Australia, the UK and the US. All GWAS subjects were genotyped
using Illumina arrays (Illumina, California, USA) [28].
A sample of 1140 MS cases and 1140 healthy controls from
Australia and New Zealand were used as a replication cohort in
this study (Table 1). Australian MS cases were volunteers recruited
from Adelaide, Brisbane, Gold Coast, Hobart, Melbourne,
Newcastle, Perth and Sydney. MS cases from New Zealand were
recruited through a national prevalence survey. All cases had
definite, clinically definite, or laboratory-supported definite MS
according to the McDonald and Poser criteria, respectively. All
controls were from the Australian Bone Marrow Donor Registry
with no history of clinically isolated syndrome or MS at the time of
collection. All samples were obtained from individuals of
European ancestry from Australia and New Zealand.
SNP selection
Of the top 7 directly genotyped SNPs in TAM receptor and
ligand genes in the ANZgene GWAS, 6 were in the MERTK gene
(Table S1). We therefore took a candidate gene approach focusing
on MERTK. Using the total of 22 directly genotyped SNPs in the
MERTK gene as proxies, non-genotyped SNPs that were tagged in
the GWAS dataset were imputed using Beagle (see below). Based
on this information, we selected 28 SNPs that showed suggestive
association with MS to interrogate in the replication phase. These
included the top 6 genotyped SNPs in the ANZgene GWAS, plus
22 imputed SNPs that showed suggestive association with MS.
Genotyping
Subjects in the replication cohort were genotyped using the
Sequenom MassARRAY system and iPLEX Gold chemistry
under conditions recommended by the manufacturer (Sequenom,
California, USA). Genomic DNA from all subjects was extracted
as described in the ANZgene GWAS [28].
Imputation
Imputation of tagged, un-genotyped SNPs in the GWAS cohort
was performed with Beagle v3.2.0 (http://faculty.washington.edu/
browning/beagle/beagle.html) [29] using the default settings.
Analyses were performed to impute the most likely values of
missing genotypes, and to calculate posterior genotype probabil-
ities at all HapMap SNPs. To do this, data from unphased
Hapmap phase II CEU (USA residents of northern and western
European ancestry) individuals (release 24, build 36, forward
strand) was used as a reference panel.
Statistical analysis
For SNPs that were genotyped in both the GWAS and
replication cohorts, association analysis was performed using the
Table 1. Replication sample data.
MS patients (n=1140) Controls (n=1140)
Mean age of onset ±
standard deviation
1:
33.85610.14 N/A
Sex:
Female 816 669
Male 247 450
Unknown 77 21
MS disease course: N/A
RRMS 632
SPMS 369
PPMS 58
Single 1
Unknown 80
MS: multiple sclerosis; N/A: not applicable; RRMS: relapsing-remitting multiple
sclerosis; SPMS: secondary-progressive multiple sclerosis; PPMS:
primary-progressive multiple sclerosis; Single: first demyelinating event.
1Age information only available for 1069 MS patients and the mean is
calculated as such.
doi:10.1371/journal.pone.0016964.t001
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For SNPs that were imputed in either the GWAS or
replication subjects, posterior allele dosages were used to
perform the association analysis. The posterior allele dosage is
twice the posterior genotype probability of the AA genotype
plus the posterior genotype probability of the AB genotype
(where A represents one of the alleles for the marker and B the
other allele). Linear regression of allele dosages on case-control
status was performed to test for association, with adjustment
for sample group (discovery/replication) in the combined
dataset.
Linkage disequilibrium analysis
To investigate linkage disequilibrium (LD) between SNPs, data
from Hapmap phase II CEU individuals (release 24, build 36,
forward strand) was analysed using Haploview v4.2 (http://www.
broadinstitute.org/haploview) [31].
Figure 1. Location of SNPs within the MERTK gene. A. Schematic of the MERTK gene (Accession Number NG_011607.1, Chromosome 2:
12,656,056-112,787,138 forward strand). Black rectangles indicate the 19 exons of MERTK and grey lines show physical location of the 12 replicated
SNPs. B. Linkage disequilibrium (LD) structure for all Hapmap phase II CEU SNPs (release 24, build 36, forward strand) in the MERTK gene, visualized
using Haploview v4.2 (ref. 29). Lines point out the 12 replicated SNPs. Inter-SNP LD is represented by shaded squares, with red shading indicating
strongest LD (D9=1), and white indicating weak or no LD between SNPs.
doi:10.1371/journal.pone.0016964.g001
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Hardy-Weinberg equilibrium of SNPs was determined by using
the –hardy command in PLINK v1.07. SNPs in significant Hardy-
Weinberg disequilibrium (p,10
27) in control groups were
excluded from further analysis.
Results and Discussion
Our discovery dataset consisted of genotype data of 1618 MS
cases and 3413 controls of European ancestry from a recent
GWAS [28]. Of the top 7 directly genotyped SNPs in genes
encoding TAM receptors and their ligands that showed suggestive
p-values for association with MS in the discovery dataset, 6 were in
the MERTK gene (Chromosome 2q14.1, Accession Number
NG_011607.1) (Table S1). Based on association analysis of
directly genotyped and imputed SNPs in the discovery dataset,
we conducted a replication study with a candidate gene approach
focusing on 28 SNPs within the MERTK gene. In our independent
replication cohort, 12 of the 28 interrogated SNPs replicated, with
association p-values of less than 0.05 and odds ratios going in the
same direction as in the discovery dataset (Fig. 1A, Table 2). All 12
replicated SNPs had p-values of less than 10
-4 when the discovery
and replication cohorts were combined. Notable SNPs with
combined p-values of less than 10
25 were rs867311, rs12477716,
rs17835605, rs4278932, rs4528767, rs17174870 and rs1516629.
Linkage disequilibrium analysis showed all 12 replicated SNPs to
be in strong LD with each other, with D9=1 and r
2.0.95 for all
pairs of SNPs (Fig. 1B).
We included the top 6 genotyped SNPs from the discovery
dataset with p-values of less than 0.05 in the 28 SNPs that were
genotyped in our replication cohort. Of these SNPs, only
rs11884641 replicated, with the other 5 showing p-values of
greater than 0.05 in the replication cohort (Table 2).
Although the SNPs interrogated in this study do not reach the
level of genome-wide significance (p,5610
28), our study
nevertheless identifies 12 SNPs that replicate in two independent
cohorts of MS cases and controls, and that reach a level of
significance required for a candidate gene approach. This provides
strong evidence that the MERTK gene is associated with MS
susceptibility. The 12 replicated SNPs are all common variants;
although all are intronic and in strong LD with each other, they
may be tagging potentially rare causal variants within coding
regions of the gene. Fine mapping of the MERTK gene and
interrogation of different populations with larger sample sizes may
aid in determining the exact causal variants. As MS is a genetically
complex disease, the MERTK gene may also represent one of
many disease loci that confer susceptibility to MS when present in
combination.
The TAM receptors have been shown to be major players in
regulation of the immune response [17,18,19]. Triple TAM
receptor mutants develop widespread autoimmunity, with in-
creased circulating levels of autoantibodies [17]. The autoimmu-
nity phenotype showed a gene dosage effect, with less severe
autoimmunity in mice deficient for two TAM receptors, and an
even milder, although still pronounced effect in mice deficient for
just one TAM receptor [17]. The role of MERTK in regulating
the immune response has been extensively examined, especially in
relation to its role in the phagocytosis of apoptotic cells. It has been
shown that MERTK knockout mice have macrophages deficient
in their ability to clear apoptotic cells, leading to the development
of a progressive systemic lupus erythematosus-like phenotype
[20,32]. In the immune system, MERTK has also been implicated
in regulation of dendritic cell activation [33], T cell selection and
tolerance [34,35], and B cell homeostasis and tolerance [36,37].
Multiple sclerosis has often been classified as an autoimmune
disease, and the obvious inflammatory response observed in the
disease strongly supports this hypothesis. In light of previous
studies implicating the TAM receptors in regulating both
demyelination and autoimmune responses in both experimental
animals and human MS lesions (for review, see ref. [38]), the
present study provides strong evidence that MERTK represents a
genuine MS susceptibility gene.
In conclusion, this candidate gene study has identified an
association of MS with 12 SNPs in the MERTK gene that
replicated in two independent cohorts of MS cases and controls,
an association that is particularly compelling given the previous
studies implicating TAM receptor signalling in demyelination and
autoimmunity. Further fine mapping studies will be required to
determine the causal variant or variants.
Supporting Information
Table S1 SNP associations of all directly genotyped TAM
receptor and ligand genes in the top 300,000 SNPs of the
discovery (GWAS) dataset.
(DOC)
Acknowledgments
We thank individuals in Australia and New Zealand for supporting this
research. We thank Laura Johnson for technical assistance. Replication
genotyping was conducted at the Murdoch Children’s Research Institute
Sequenom Platform Facility.
" ANZGene Consortium. Melanie Bahlo
1, David R Booth
2, Simon
Broadley
3,4, Matthew A Brown
5,6, Brian L Browning
7,S h a r o nR
Browning
8, Helmut Butzkueven
9–11, William M Carroll
12–14, Patrick
Danoy
5, Judith Field
10,15, Simon J Foote
16, Lyn Griffiths
17, Robert N
Heard
2, Allan G Kermode
12–13, Trevor J Kilpatrick
10,14,18, Jeanette
Lechner-Scott
19, 20, Pablo Moscato
20, 21, Victoria M Perreau
14, Rodney J
Scott
19,20,21, Mark Slee
22, Jim Stankovich
16, Graeme J Stewart
2, Bruce V
Taylor
16, and James Wiley
10 (Chair)
Affiliations for Authors. (AUS=Australia, NZ=New Zealand,
VIC=Victoria, NSW=New South Wales, QLD=Queensland, South
Australia=SA, TAS=Tasmania, WA=Western Australia).
1 The Walter and Eliza Hall Institute of Medical Research, Parkville,
VIC, AUS, 3050.
2 The Westmead Millenium Institute, Westmead, NSW, Australia 2145.
3 School of Medicine, Griffith University, QLD, Australia, 4222.
4 Department of Neurology, Gold Coast Hospital, QLD, Australia 4215.
5 The Diamantina Institute of Cancer, Immunology and Metabolic
Medicine, Princess Alexandra Hospital, University of Queensland,
Brisbane, QLD, Australia 4102.
6 Botnar Research Centre, Nuffield Department of Orthopaedic
Surgery, University of Oxford, Oxford, OX3 7BN, UK.
7 Division of Medical Genetics, Department of Medicine, University of
Washington, Seattle, WA 98195, USA.
8 Department of Biostatistics, University of Washington, Seattle, WA
98195, USA.
9 Department of Medicine, University of Melbourne, Melbourne, VIC,
Australia.
10 Florey Neuroscience Institutes, University of Melbourne, Melbourne,
VIC, Australia.
11 Department of Neurology, Box Hill Hospital, VIC, Australia.
12 Sir Charles Gairdner Hospital, Nedlands, WA, AUS 6009.
13 Australian Neuromuscular Research Institute, Nedlands WA, AUS
6009.
14 Centre for Neuromuscular Research and Neurological Disorders,
University of Western Australia, Nedlands, WA, Australia.
15 Centre for Neuroscience, University of Melbourne, VIC, Australia
3010.
16 Menzies Research Institute, University of Tasmania, Hobart,
Tasmania, Australia. 7001.
17 Genomics Research Centre, Griffith University, QLD, Australia
4222.
MERTK Is Associated with Multiple Sclerosis
PLoS ONE | www.plosone.org 5 February 2011 | Volume 6 | Issue 2 | e1696418 Royal Melbourne Hospital, Parkville, VIC, Australia 3050.
19 John Hunter Hospital, Hunter New England Health Service,
Newcastle NSW, Australia 2310.
20 Hunter Medical Research Institute, Newcastle, NSW, Australia 2308.
21 Centre for Bioinformatics, Biomarker Discovery and Information-
based Medicine, University of Newcastle, NSW, Australia 2308.
22 School of Medicine, Department of Neurology, Flinders University of
South Australia, Bedford Park, Adelaide, SA, Australia 5042.
Author Contributions
Conceived and designed the experiments: GZMM JS TJK MDB JF.
Performed the experiments: GZMM JF. Analyzed the data: GZMM JS JF.
Contributed reagents/materials/analysis tools: GZMM JS TJK MDB JF.
Wrote the paper: GZMM JS TJK MDB JF.
References
1. Compston A, Coles A (2008) Multiple sclerosis. Lancet 372: 1502–1517.
2. Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, et al. (2007) Risk
alleles for multiple sclerosis identified by a genomewide study. N Engl J Med
357: 851–862.
3. Masterman T, Ligers A, Olsson T, Andersson M, Olerup O, et al. (2000) HLA-
DR15 is associated with lower age at onset in multiple sclerosis. Ann Neurol 48:
211–219.
4. Rubio JP, Stankovich J, Field J, Tubridy N, Marriott M, et al. (2008) Replication
of KIAA0350, IL2RA, RPL5 and CD58 as multiple sclerosis susceptibility genes
in Australians. Genes Immun 9: 624–630.
5. International Multiple Sclerosis Genetics Consortium (2009) The expanding
genetic overlap between multiple sclerosis and type I diabetes. Genes Immun 10:
11–14.
6. De Jager PL, Jia X, Wang J, de Bakker PI, Ottoboni L, et al. (2009) Meta-
analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as
new multiple sclerosis susceptibility loci. Nat Genet 41: 776–782.
7. Jakkula E, Leppa V, Sulonen AM, Varilo T, Kallio S, et al. (2010) Genome-wide
association study in a high-risk isolate for multiple sclerosis reveals associated
variants in STAT3 gene. Am J Hum Genet 86: 285–291.
8. International Multiple Sclerosis Genetics Consortium (2010) Comprehensive
follow-up of the first genome-wide association study of multiple sclerosis
identifies KIF21B and TMEM39A as susceptibility loci. Hum Mol Genet 19:
953–962.
9. Ban M, Goris A, Lorentzen AR, Baker A, Mihalova T, et al. (2009) Replication
analysis identifies TYK2 as a multiple sclerosis susceptibility factor. Eur J Hum
Genet 17: 1309–1313.
10. Godowski PJ, Mark MR, Chen J, Sadick MD, Raab H, et al. (1995)
Reevaluation of the roles of protein S and Gas6 as ligands for the receptor
tyrosine kinase Rse/Tyro 3. Cell 82: 355–358.
11. Stitt TN, Conn G, Gore M, Lai C, Bruno J, et al. (1995) The anticoagulation
factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of
receptor tyrosine kinases. Cell 80: 661–670.
12. Nagata K, Ohashi K, Nakano T, Arita H, Zong C, et al. (1996) Identification of
the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky,
and Mer receptor tyrosine kinases. J Biol Chem 271: 30022–30027.
13. Yagami T, Ueda K, Asakura K, Sakaeda T, Nakazato H, et al. (2002) Gas6
rescues cortical neurons from amyloid beta protein-induced apoptosis.
Neuropharmacology 43: 1289–1296.
14. Shankar SL, O’Guin K, Cammer M, McMorris FA, Stitt TN, et al. (2003) The
growth arrest-specific gene product Gas6 promotes the survival of human
oligodendrocytes via a phosphatidylinositol 3-kinase-dependent pathway.
J Neurosci 23: 4208–4218.
15. Shankar SL, O’Guin K, Kim M, Varnum B, Lemke G, et al. (2006) Gas6/Axl
signaling activates the phosphatidylinositol 3-kinase/Akt1 survival pathway to
protect oligodendrocytes from tumor necrosis factor alpha-induced apoptosis.
J Neurosci 26: 5638–5648.
16. Li R, Chen J, Hammonds G, Phillips H, Armanini M, et al. (1996) Identification
of Gas6 as a growth factor for human Schwann cells. J Neurosci 16: 2012–2019.
17. Lu Q, Lemke G (2001) Homeostatic regulation of the immune system by
receptor tyrosine kinases of the Tyro 3 family. Science 293: 306–311.
18. Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G (2007) TAM
receptors are pleiotropic inhibitors of the innate immune response. Cell 131:
1124–1136.
19. Lemke G, Rothlin CV (2008) Immunobiology of the TAM receptors. Nat Rev
Immunol 8: 327–336.
20. Scott RS, McMahon EJ, Pop SM, Reap EA, Caricchio R, et al. (2001)
Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature 411:
207–211.
21. Anderson HA, Maylock CA, Williams JA, Paweletz CP, Shu H, et al. (2003)
Serum-derived protein S binds to phosphatidylserine and stimulates the
phagocytosis of apoptotic cells. Nat Immunol 4: 87–91.
22. Hiremath MM, Saito Y, Knapp GW, Ting JP, Suzuki K, et al. (1998)
Microglial/macrophage accumulation during cuprizone-induced demyelination
in C57BL/6 mice. J Neuroimmunol 92: 38–49.
23. Matsushima GK, Morell P (2001) The neurotoxicant, cuprizone, as a model to
study demyelination and remyelination in the central nervous system. Brain
Pathol 11: 107–116.
24. Hiremath MM, Chen VS, Suzuki K, Ting JP, Matsushima GK (2008) MHC
class II exacerbates demyelination in vivo independently of T cells.
J Neuroimmunol 203: 23–32.
25. Binder MD, Cate HS, Prieto AL, Kemper D, Butzkueven H, et al. (2008) Gas6
deficiency increases oligodendrocyte loss and microglial activation in response to
cuprizone-induced demyelination. J Neurosci 28: 5195–5206.
26. Hoehn HJ, Kress Y, Sohn A, Brosnan CF, Bourdon S, et al. (2008) Axl-/- mice
have delayed recovery and prolonged axonal damage following cuprizone
toxicity. Brain Res 1240: 1–11.
27. Weinger JG, Omari KM, Marsden K, Raine CS, Shafit-Zagardo B (2009) Up-
regulation of soluble Axl and Mer receptor tyrosine kinases negatively correlates
with Gas6 in established multiple sclerosis lesions. Am J Pathol 175: 283–293.
28. Australia and New Zealand Multiple Sclerosis Genetics Consortium (2009)
Genome-wide association study identifies new multiple sclerosis susceptibility
loci on chromosomes 12 and 20. Nat Genet 41: 824–828.
29. Browning BL, Browning SR (2009) A unified approach to genotype imputation
and haplotype-phase inference for large data sets of trios and unrelated
individuals. Am J Hum Genet 84: 210–223.
30. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007)
PLINK: a tool set for whole-genome association and population-based linkage
analyses. Am J Hum Genet 81: 559–575.
31. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and
visualization of LD and haplotype maps. Bioinformatics 21: 263–265.
32. Cohen PL, Caricchio R, Abraham V, Camenisch TD, Jennette JC, et al. (2002)
Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking
the c-mer membrane tyrosine kinase. J Exp Med 196: 135–140.
33. Sen P, Wallet MA, Yi Z, Huang Y, Henderson M, et al. (2007) Apoptotic cells
induce Mer tyrosine kinase-dependent blockade of NF-kappaB activation in
dendritic cells. Blood 109: 653–660.
34. Wallet MA, Flores RR, Wang Y, Yi Z, Kroger CJ, et al. (2009) MerTK regulates
thymic selection of autoreactive T cells. Proc Natl Acad Sci U S A 106:
4810–4815.
35. Wallet MA, Sen P, Flores RR, Wang Y, Yi Z, et al. (2008) MerTK is required
for apoptotic cell-induced T cell tolerance. J Exp Med 205: 219–232.
36. Shao WH, Eisenberg RA, Cohen PL (2008) The Mer receptor tyrosine kinase is
required for the loss of B cell tolerance in the chronic graft-versus-host disease
model of systemic lupus erythematosus. J Immunol 180: 7728–7735.
37. Shao WH, Kuan AP, Wang C, Abraham V, Waldman MA, et al. (2010)
Disrupted Mer receptor tyrosine kinase expression leads to enhanced MZ B-cell
responses. J Autoimmun.
38. Binder MD, Kilpatrick TJ (2009) TAM receptor signalling and demyelination.
Neurosignals 17: 277–287.
MERTK Is Associated with Multiple Sclerosis
PLoS ONE | www.plosone.org 6 February 2011 | Volume 6 | Issue 2 | e16964